Stockscreener 앱 받기
1.23
0.81%
-0.01
시간 외 거래:
1.23
전일 마감가:
$1.24
열려 있는:
$1.24
하루 거래량:
692.23K
Relative Volume:
1.03
시가총액:
$67.78M
수익:
-
순이익/손실:
$-41.07M
주가수익비율:
-1.6622
EPS:
-0.74
순현금흐름:
$-32.97M
1주 성능:
+6.96%
1개월 성능:
+18.27%
6개월 성능:
-49.17%
1년 성능:
-29.71%
1일 변동 폭
$1.11
$1.24
1주일 범위
$1.11
$1.29
52주 변동 폭
$0.726
$4.2684
Galectin Therapeutics Inc Stock (GALT) Company Profile
명칭
Galectin Therapeutics Inc
전화
678-620-3186
주소
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
GALT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
1.23 | 67.78M | 0 | -41.07M | -32.97M | -0.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-08-13 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-13 | 개시 | B. Riley FBR | Buy |
| 2017-12-07 | 재확인 | H.C. Wainwright | Buy |
| 2017-11-28 | 재확인 | H.C. Wainwright | Buy |
| 2017-10-19 | 개시 | ROTH Capital | Buy |
| 2017-03-30 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2016-10-03 | 다운그레이드 | FBR & Co. | Outperform → Mkt Perform |
| 2016-09-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2016-09-28 | 다운그레이드 | ROTH Capital | Buy → Sell |
| 2016-03-28 | 재개 | H.C. Wainwright | Buy |
| 2015-09-21 | 개시 | H.C. Wainwright | Buy |
| 2014-08-01 | 다운그레이드 | Aegis Capital | Buy → Hold |
| 2014-07-30 | 재확인 | MLV & Co | Buy |
| 2014-07-29 | 재확인 | MLV & Co | Buy |
| 2014-04-02 | 재확인 | MLV & Co | Buy |
| 2014-02-10 | 재확인 | Aegis Capital | Buy |
| 2014-01-09 | 재확인 | Aegis Capital | Buy |
| 2013-12-03 | 개시 | MLV & Co | Buy |
| 2013-08-19 | 재확인 | Aegis Capital | Buy |
모두보기
Galectin Therapeutics Inc 주식(GALT)의 최신 뉴스
Galectin Therapeutics (NASDAQ: GALT) Updates Corporate Presentation and Discloses Forward-Looking StatementsGalectin Therapeutics Inc. (the “Company”) updated its corporate presentation on January 13, 2025, which will be utilized in interactions such - Defense World
Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Purchased by Wealth Enhancement Advisory Services LLC - Defense World
Galectin Therapeutics Target of Unusually High Options Trading (NASDAQ:GALT) - MarketBeat
Comparing Galectin Therapeutics (NASDAQ:GALT) and Avenue Therapeutics (NASDAQ:ATXI) - Defense World
Galectin Therapeutics to Present at the 2025 MASH-TAG Conference - The Manila Times
Galectin Therapeutics to Present Breakthrough NAVIGATE Trial Results at MASH-TAG 2025 Conference - StockTitan
Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Bought by Barclays PLC - Defense World
Geode Capital Management LLC Acquires 20,817 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Bought by State Street Corp - Defense World
Galectin Therapeutics director Harold Shlevin purchases $7,539 in common stock - Investing.com Nigeria
Galectin Therapeutics Director Increases Stake Amid Strong Momentum, Despite Trial Setbacks - HPBL
Galectin Therapeutics (NASDAQ:GALT) Lowered to “Sell” Rating by StockNews.com - Defense World
Galectin Therapeutics (NASDAQ:GALT) Downgraded by StockNews.com to "Sell" - MarketBeat
Galectin Therapeutics Inc. (NASDAQ:GALT) Short Interest Up 41.1% in December - MarketBeat
North American Morning Briefing : Boeing Stock -2- - Marketscreener.com
Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Sold by Sanctuary Advisors LLC - Defense World
H.C. Wainwright cuts Galectin stock rating to Neutral By Investing.com - Investing.com Canada
Galectin Therapeutics (NASDAQ:GALT) Given “Neutral” Rating at HC Wainwright - Defense World
HC Wainwright & Co. Downgrades Galectin Therapeutics (GALT) - MSN
HC Wainwright Reiterates Neutral Rating for Galectin Therapeutics (NASDAQ:GALT) - MarketBeat
Eldred Kary buys $11,044 in Galectin Therapeutics shares By Investing.com - Investing.com Australia
Joel Lewis Sells 56,000 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) Stock - MarketBeat
Insider Selling: Galectin Therapeutics Inc. (NASDAQ:GALT) Insider Sells 13,654 Shares of Stock - MarketBeat
Galectin Therapeutics Inc. (NASDAQ:GALT) CFO Sells $35,600.00 in Stock - MarketBeat
Eldred Kary buys $11,044 in Galectin Therapeutics shares - Investing.com India
Galectin Therapeutics director Kevin Freeman acquires $8,134 in stock By Investing.com - Investing.com Australia
Galectin Therapeutics director Kevin Freeman acquires $8,134 in stock - Investing.com India
Galectin Therapeutics CEO Lewis Joel sells $49,610 in stock By Investing.com - Investing.com Canada
Galectin Therapeutics director Richard Zordani buys $8,164 in stock By Investing.com - Investing.com Nigeria
Galectin Therapeutics’ chief medical officer sells $12,044 in shares By Investing.com - Investing.com Nigeria
Galectin Therapeutics director Richard Zordani buys $8,164 in stock - Investing.com India
Galectin therapeutics CFO Jack Callicutt sells $35,492 in stock By Investing.com - Investing.com Canada
Galectin Therapeutics CEO Lewis Joel sells $49,610 in stock - Investing.com
Galectin Therapeutics' chief medical officer sells $12,044 in shares - Investing.com
Liver Cirrhosis Therapeutics Market Size in the 7MM was ~USD 3,100 Million in 2023, is further anticipated to increase with a siginificant CAGR by 2034 and estimated DelveInsight - Barchart
Liver Cirrhosis Therapeutics Market Size in the 7MM was ~USD - openPR
Galectin Therapeutics Announces Positive Results from NAVIGATE Clinical Trial - Defense World
Galectin drops as trial for lead asset fails in MASH - MSN
Belapectin shows promise in liver disease trial - Investing.com India
Dow Surges Over 600 Points, Gold Jumps 1.5% - Benzinga
Galectin Therapeutics Shares Drop 54% After Treatment Misses Trial Endpoint - MarketWatch
Nasdaq Jumps Over 300 Points, Novo Nordisk Shares Spike Higher - Benzinga
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Galectin Therapeutics stock hits 52-week low at $1.23 - Investing.com
Phase III MASH Miss Sends Galectin Stock Tumbling - BioSpace
Dow Surges 100 Points, Carnival Earnings Top Views - Benzinga
Galectin Therapeutics stock hits 52-week low at $1.23 By Investing.com - Investing.com Nigeria
Belapectin shows promise in liver disease trial By Investing.com - Investing.com South Africa
Galectin stock drops after MASH trial data (GALT:NASDAQ) - Seeking Alpha
Galectin Therapeutics Inc (GALT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):